In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• Andrew Gigax, Head of European Pharma Services M&A at William Blair


• Jennifer Chadwick, Founder and Principal at Jennifer Chadwick Consulting


• Sabina Ouimet Storrs, Principal at GHO Capital Partners


• Jason Foss, Head of Corporate Development at Bora Pharmaceuticals

Your host, Raman Sehgal, speaks with his guests about the pharmaceutical and biotechnology ecosystem, including:

• How market stabilisation has been overtaken by the need for adaptation in times of uncertainty


• Disciplined and deeper M&A, with heightened scrutiny, buyer and seller disconnect, and a sharper focus on operational efficiency


• The growing demand for bispecifics, radiopharma, isotopes, and other emerging segments


• Why the “picks and shovels” that serve multiple modalities are where opportunity lies in pharma services


• Why the US remains the hottest market, and how AI adoption has mainly focused on workflow so far


• The shifts and trends that could reshape pharma services in the years ahead

Molecule to Market is sponsored by Bora Pharma, Charles River and Lead Candidate, and supported by Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!